Comparative Efficacy of Azithromycin Distribution Strategies on Childhood Mortality in Niger
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 11th, 2024
|
To address childhood mortality in low-resource countries, the World Health Organization previously recommended biannual mass distribution of azithromycin to children aged 1 to 59 months. However, concerns over rising antimicrobial resistance led to a revised recommendation limiting the intervention to children between 1 and 11 months of age. In response, the Bill and Melinda Gates Foundation funded a study to assess the effectiveness of this shorter 1-11 month regimen compared to the original 1-59 month recommendation.
The community study was conducted in Niger and involved 1,273 communities, primarily in the southern region of the country. Overall, more than 380,000 children aged 1 to 59 months participated. The communities were randomly assigned to one of three treatment groups: 1) placebo for children aged 1-59 months; 2) azithromycin for children aged 1-59 months; and 3) azithromycin for infants aged 1-11 months, with placebo for children aged 12-59 months. Children with macrolide allergies were excluded from the study, and treatment was administered biannually at a dosage of 20 mg per kilogram of body weight in oral suspension. After two years, 5,503 deaths were recorded. The researchers found that communities administering azithromycin to children aged 1-59 months experienced a 14% lower risk of mortality compared to those where distribution was limited to infants aged 1-11 months. Additionally, the new recommendation for the 1-11 month age group did not lead to a significant reduction in mortality compared to the placebo group. These findings align with existing literature, suggesting that azithromycin may reduce the risk of death associated with malaria, respiratory infections, and dysentery.
The community study was conducted in Niger and involved 1,273 communities, primarily in the southern region of the country. Overall, more than 380,000 children aged 1 to 59 months participated. The communities were randomly assigned to one of three treatment groups: 1) placebo for children aged 1-59 months; 2) azithromycin for children aged 1-59 months; and 3) azithromycin for infants aged 1-11 months, with placebo for children aged 12-59 months. Children with macrolide allergies were excluded from the study, and treatment was administered biannually at a dosage of 20 mg per kilogram of body weight in oral suspension. After two years, 5,503 deaths were recorded. The researchers found that communities administering azithromycin to children aged 1-59 months experienced a 14% lower risk of mortality compared to those where distribution was limited to infants aged 1-11 months. Additionally, the new recommendation for the 1-11 month age group did not lead to a significant reduction in mortality compared to the placebo group. These findings align with existing literature, suggesting that azithromycin may reduce the risk of death associated with malaria, respiratory infections, and dysentery.